Population Pharmacokinetics Modeling and Simulation of Deutenzalutamide, A Novel Androgen Receptor Antagonist, in Patients With Metastatic Castration-Resistant Prostate Cancer.

Autor: Liu Y; Cancer Center, West China Hospital, Sichuan University, Chengdu, China.; Clinical Trial Center, NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug West China Hospital, Sichuan University, Chengdu, China., He Y; Cancer Center, West China Hospital, Sichuan University, Chengdu, China.; Clinical Trial Center, NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug West China Hospital, Sichuan University, Chengdu, China., Qi X; Cancer Center, West China Hospital, Sichuan University, Chengdu, China.; School of Pharmacy, Chengdu Medical College, Chengdu, China., Li X; Hinova Pharmaceuticals Inc., Chengdu, China., Zhou Y; Hinova Pharmaceuticals Inc., Chengdu, China., Chen Y; Hinova Pharmaceuticals Inc., Chengdu, China., Wang Z; Cancer Center, West China Hospital, Sichuan University, Chengdu, China.; Clinical Trial Center, NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug West China Hospital, Sichuan University, Chengdu, China., Zheng L; Cancer Center, West China Hospital, Sichuan University, Chengdu, China.; Clinical Trial Center, NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug West China Hospital, Sichuan University, Chengdu, China.
Jazyk: angličtina
Zdroj: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2024 Dec; Vol. 13 (12), pp. 1291-1300. Date of Electronic Publication: 2024 Oct 04.
DOI: 10.1002/cpdd.1477
Abstrakt: Deutenzalutamide is a new molecular entity androgen receptor antagonist. The primary aim of this study was to develop a population pharmacokinetic model of deutenzalutamide and evaluate effects of intrinsic and extrinsic factors on pharmacokinetics. A nonlinear mixed-effects modeling approach was performed to develop the population pharmacokinetic of deutenzalutamide using data from 1 Phase I trial of deutenzalutamide. Goodness-of-fit plots, prediction-corrected visual predictive check, and bootstrap analysis were carried out to evaluate the final model. Simulation for the developed model was used to evaluate the covariate effects on the pharmacokinetics of deutenzalutamide. A 2-compartment model with first-order absorption and elimination from the central compartment was established for deutenzalutamide. The final covariate included body weight on peripheral compartment volume. This is the first research developing the population pharmacokinetic model of deutenzalutamide in patients with metastatic castration-resistant prostate cancer, and it is expected to support the future clinical administration of deutenzalutamide.
(© 2024 The Author(s). Clinical Pharmacology in Drug Development published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.)
Databáze: MEDLINE
Externí odkaz: